Bayer presents new analyses for VitrakviŽ (larotrectinib) in adult and pediatric patients with TRK fusion cancer with solid tumors, and new data in primary central nervous system tumors and brain metastases

Thursday, May 16, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Annual Meeting of the American Society of Clinical Oncology (ASCO) 2019



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store